Trial Profile

SAFETY AND EFFICACY OF APIXABAN AND ENOXAPARIN IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY AND TOTAL KNEE ARTHROPLASTY: A PROSPECTIVE OBSERVATIONAL STUDY

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Enoxaparin sodium
Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
Focus Therapeutic Use

Most Recent Events

29 Jun 2021 Primary endpoint has not been met. (Death), as per Results published in the British Journal of Clinical Pharmacology
29 Jun 2021 Primary endpoint has not been met. (Pulmonary Embolism), as per Results published in the British Journal of Clinical Pharmacology
29 Jun 2021 Primary endpoint has not been met. (Symptomatic DVT), as per Results published in the British Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com